tirzepatide off the market A Major GLP-1 Drug Shortage Is Over. Some Patients Aren't Celebrating FDA says the tirzepatide weight-loss

This means your body usually has plenty of glutamate and glycine, but it runs out of cysteine first

It's the process

Abdominal fat is sometimes called visceral fat because it surrounds the organs

A real-world JAMA Internal Medicine study of 18,386 propensity-matched patients found tirzepatide users were roughly twice as likely to hit 10%+ weight loss within a year

At a glance Retatrutide is an investigational weekly injection from Eli Lilly, not yet licensed in the UK It targets three hormone receptors at once GLP-1, GIP and glucagon earning it the nickname "triple G" It reduces appetite, improves blood sugar, and appears to nudge resting energy expenditure upwards Phase 2 trial participants lost an average of around 24% of body weight over 48 weeks at the top dose Side effects mirror existing GLP-1 medications: nausea, mild gut symptoms, reduced appetite Expected UK approval is 18-24 months away pending Phase 3 results and MHRA review The basics: what retatrutide is Retatrutide is an investigational weekly injection being developed by Eli Lilly for weight loss and related metabolic conditions